{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:41Z","timestamp":1793745341016,"version":"4.6.1"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00352"],"award-info":[{"award-number":["CB16\/12\/00352"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["EPAEC222641CICS"],"award-info":[{"award-number":["EPAEC222641CICS"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FISPI22\/01538"],"award-info":[{"award-number":["FISPI22\/01538"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["SA222P23"],"award-info":[{"award-number":["SA222P23"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2022-136409OB-I00"],"award-info":[{"award-number":["PID2022-136409OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008055","name":"Fundaci\u00f3n Eugenio Rodr\u00edguez Pascual","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008055","id-type":"DOI","asserted-by":"publisher"}]},{"name":"In\u00e9s de Pablo Llorens"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02632-7","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:04:05Z","timestamp":1774490645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers"],"prefix":"10.1186","volume":"25","author":[{"given":"Luis","family":"Luna-Ram\u00edrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3sula","family":"Garc\u00eda-Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Baltan\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2632_CR1","first-page":"178","volume":"1786","author":"L Buday","year":"2008","unstructured":"Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta. 2008;1786:178\u201387.","journal-title":"Biochim Biophys Acta"},{"key":"2632_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm2438","volume":"9","author":"AE Karnoub","year":"2008","unstructured":"Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2632_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/1947601911408081","volume":"2","author":"E Castellano","year":"2011","unstructured":"Castellano E, Santos E. Functional Specificity of Ras isoforms: so similar but so different. Genes Cancer. 2011;2:216\u201331.","journal-title":"Genes Cancer"},{"key":"2632_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00149-1","volume":"112","author":"SM Margarit","year":"2003","unstructured":"Margarit SM, Sondermann H, Hall BE, Nagar B, Hoelz A, Pirruccello M, et al. Structural evidence for feedback activation by Ras\u00b7GTP of the Ras-specific nucleotide exchange factor SOS. Cell. 2003;112:685\u201395.","journal-title":"Cell"},{"key":"2632_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/45822","volume":"401","author":"G Scita","year":"1999","unstructured":"Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S, et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature. 1999;401:290\u20133.","journal-title":"Nature"},{"key":"2632_CR6","doi-asserted-by":"publisher","first-page":"188445","DOI":"10.1016\/j.bbcan.2020.188445","volume":"1874","author":"FC Baltan\u00e1s","year":"2020","unstructured":"Baltan\u00e1s FC, Zarich N, Rojas-Caba\u00f1eros JM, Santos E. SOS GEFs in health and disease. Biochim Biophys Acta Rev Cancer. 2020;1874:188445.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2632_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/298343a0","volume":"298","author":"E Santos","year":"1982","unstructured":"Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature. 1982;298:343\u20137.","journal-title":"Nature"},{"key":"2632_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/297474a0","volume":"297","author":"LF Parada","year":"1982","unstructured":"Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 1982;297:474\u20138.","journal-title":"Nature"},{"key":"2632_CR9","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1073\/pnas.79.11.3637","volume":"79","author":"CJ Der","year":"1982","unstructured":"Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci. 1982;79:3637\u201340.","journal-title":"Proc Natl Acad Sci"},{"key":"2632_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/genes12050681","volume":"12","author":"A Fern\u00e1ndez-Medarde","year":"2021","unstructured":"Fern\u00e1ndez-Medarde A, De Las Rivas J, Santos E. 40 Years of RAS\u2014A Historic Overview. Genes (Basel). 2021;12:681.","journal-title":"Genes (Basel)"},{"key":"2632_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00001813-200103000-00001","volume":"12","author":"M Crul","year":"2001","unstructured":"Crul M, de Klerk GJ, Beijnen JH, Schellens JH. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs. 2001;12:163\u201384.","journal-title":"Anticancer Drugs"},{"key":"2632_CR12","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1056\/NEJMe2107884","volume":"384","author":"N Rosen","year":"2021","unstructured":"Rosen N, Finally. Effective Inhibitors of Mutant KRAS. N Engl J Med. 2021;384:2447\u20139.","journal-title":"N Engl J Med"},{"key":"2632_CR13","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2021","unstructured":"Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA approval summary: sotorasib for KRAS G12C -mutated metastatic NSCLC. Clin Cancer Res. 2021;28:1482\u20136.","journal-title":"Clin Cancer Res"},{"key":"2632_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical acquired resistance to krasg12c inhibition through a novel kras switch-ii pocket mutation and polyclonal alterations converging on ras\u2013mapk reactivation. Cancer Discov. 2021;11:1913\u201322.","journal-title":"Cancer Discov"},{"key":"2632_CR15","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021;384:2382\u201393.","journal-title":"N Engl J Med"},{"key":"2632_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, et al. KRAS Secondary mutations that confer acquired resistance to KRAS G12C Inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16:1321\u201332.","journal-title":"J Thorac Oncol"},{"key":"2632_CR17","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ncomms2173","volume":"3","author":"H-H Jeng","year":"2012","unstructured":"Jeng H-H, Taylor LJ, Bar-Sagi D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Commun. 2012;3:1168.","journal-title":"Nat Commun"},{"key":"2632_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/genes12050662","volume":"12","author":"E Sheffels","year":"2021","unstructured":"Sheffels E, Kortum RL. The Role of Wild-Type RAS in Oncogenic RAS Transformation. Genes (Basel). 2021;12:662.","journal-title":"Genes (Basel)"},{"key":"2632_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/2159-8290.CD-12-0231","volume":"3","author":"A Young","year":"2013","unstructured":"Young A, Lou D, McCormick F. Oncogenic and wild-type ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013;3:113\u201323.","journal-title":"Cancer Discov"},{"key":"2632_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0092-8674(91)90207-F","volume":"64","author":"RD Rogge","year":"1991","unstructured":"Rogge RD, Karlovich CA, Banerjee U. Genetic dissection of a neurodevelopmental pathway: Son of sevenless functions downstream of the sevenless and EGF receptor tyrosine kinases. Cell. 1991;64:39\u201348.","journal-title":"Cell"},{"key":"2632_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0092-8674(91)90065-7","volume":"67","author":"MA Simon","year":"1991","unstructured":"Simon MA, Bowtell DDL, Dodson GS, Laverty TR, Rubin GM. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell. 1991;67:701\u201316.","journal-title":"Cell"},{"key":"2632_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1126\/science.1736363","volume":"255","author":"L Bonfini","year":"1992","unstructured":"Bonfini L, Karlovich CA, Dasgupta C, Banerjee U. The Son of sevenless Gene Product: a Putative Activator of Ras. Science. 1992;255:603\u20136.","journal-title":"Science"},{"key":"2632_CR23","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1126\/science.8493579","volume":"260","author":"P Chardin","year":"1993","unstructured":"Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science. 1993;260:1338\u201343.","journal-title":"Science"},{"key":"2632_CR24","first-page":"68","volume":"66","author":"P Chardin","year":"1994","unstructured":"Chardin P, Mattei M-G. Chromosomal localization of two genes encoding human ras exchange factors: SOS1 maps to the 2p22\u2192p16 region and SOS2 to the 14q21\u2192q22 region of the human genome. Cytogenet Genome Res. 1994;66:68\u20139.","journal-title":"Cytogenet Genome Res"},{"key":"2632_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1947601911408078","volume":"2","author":"JM Rojas","year":"2011","unstructured":"Rojas JM, Oliva JL, Santos E. Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives. Genes Cancer. 2011;2:298\u2013305.","journal-title":"Genes Cancer"},{"key":"2632_CR26","doi-asserted-by":"crossref","unstructured":"Pierre S, Bats AS, Coumoul X. Understanding SOS (Son of Sevenless). Biochem Pharmacol. 2011;82:1049\u201356.","DOI":"10.1016\/j.bcp.2011.07.072"},{"key":"2632_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1101\/gad.11.3.309","volume":"11","author":"DZM Wang","year":"1997","unstructured":"Wang DZM, Hammond VE, Abud HE, Bertoncello I, McAvoy JW, Bowtell DDL. Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for sos1 in EGFR signaling and development. Genes Dev. 1997;11:309\u201320.","journal-title":"Genes Dev"},{"key":"2632_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/emboj\/19.4.642","volume":"19","author":"X Qian","year":"2000","unstructured":"Qian X, Esteban L, Vass WC, Upadhyaya C, Papageorge AG, Yienger K, et al. The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties. EMBO J. 2000;19:642\u201354.","journal-title":"EMBO J"},{"key":"2632_CR29","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1128\/MCB.20.17.6410-6413.2000","volume":"20","author":"LM Esteban","year":"2000","unstructured":"Esteban LM, Fern\u00e1ndez-Medarde A, L\u00f3pez E, Yienger K, Guerrero C, Ward JM, et al. Ras-guanine nucleotide exchange factor sos2 is dispensable for mouse growth and development. Mol Cell Biol. 2000;20:6410\u20133.","journal-title":"Mol Cell Biol"},{"key":"2632_CR30","doi-asserted-by":"publisher","first-page":"12407","DOI":"10.1073\/pnas.1104295108","volume":"108","author":"RL Kortum","year":"2011","unstructured":"Kortum RL, Sommers CL, Alexander CP, Pinski JM, Li W, Grinberg A, et al. Targeted Sos1 deletion reveals its critical role in early T-cell development. Proc Natl Acad Sci U S A. 2011;108:12407\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2632_CR31","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1128\/MCB.01026-13","volume":"33","author":"FC Baltan\u00e1s","year":"2013","unstructured":"Baltan\u00e1s FC, P\u00e9rez-Andr\u00e9s M, Ginel-Picardo A, Diaz D, Jimeno D, Liceras-Boillos P, et al. Functional redundancy of Sos1 and Sos2 for lymphopoiesis and organismal homeostasis and survival. Mol Cell Biol. 2013;33:4562\u201378.","journal-title":"Mol Cell Biol"},{"key":"2632_CR32","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.chembiol.2014.09.018","volume":"21","author":"CR Evelyn","year":"2014","unstructured":"Evelyn CR, Duan X, Biesiada J, Seibel WL, Meller J, Zheng Y. Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. Chem Biol. 2014;21:1618\u201328.","journal-title":"Chem Biol"},{"key":"2632_CR33","doi-asserted-by":"crossref","unstructured":"Han Z, Wu Q, Rao H, Xu T, Zhou C. An overview of PROTACs targeting KRAS and SOS1 as antitumor agents. Bioorg Med Chem Lett. 2025;1:125\u20136.","DOI":"10.1016\/j.bmcl.2025.130283"},{"key":"2632_CR34","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","volume":"65","author":"C Zhou","year":"2022","unstructured":"Zhou C, Fan Z, Zhou Z, Li Y, Cui R, Liu C, et al. Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations. J Med Chem. 2022;65:3923\u201342.","journal-title":"J Med Chem"},{"key":"2632_CR35","doi-asserted-by":"publisher","first-page":"12879","DOI":"10.1074\/jbc.M114.634493","volume":"290","author":"CR Evelyn","year":"2015","unstructured":"Evelyn CR, Biesiada J, Duan X, Tang H, Shang X, Papoian R, et al. Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a ras-activating enzyme. J Biol Chem. 2015;290:12879\u201398.","journal-title":"J Biol Chem"},{"key":"2632_CR36","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1073\/pnas.1812963116","volume":"116","author":"RC Hillig","year":"2019","unstructured":"Hillig RC, Sautier B, Schroeder J, Moosmayer D, Hilpmann A, Stegmann CM, et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS\u2013SOS1 interaction. Proc Natl Acad Sci U S A. 2019;116:2551\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2632_CR37","doi-asserted-by":"publisher","first-page":"101230","DOI":"10.1016\/j.tranon.2021.101230","volume":"14","author":"A Plangger","year":"2021","unstructured":"Plangger A, Rath B, Hochmair M, Funovics M, Hamilton G. Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells. Transl Oncol. 2021;14:101230.","journal-title":"Transl Oncol"},{"key":"2632_CR38","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1038\/s41401-022-00897-4","volume":"43","author":"T Wang Cxiang, Wang","year":"2022","unstructured":"Wang Cxiang, Wang T, ting, Zhang K, dong, Li Myu, Shen Q, cheng, Lu S et al. yong,. Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma. Acta Pharmacol Sin. 2022;43:2696\u2013708.","journal-title":"Acta Pharmacol Sin"},{"key":"2632_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, et al. BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142\u201357.","journal-title":"Cancer Discov"},{"key":"2632_CR40","doi-asserted-by":"publisher","first-page":"e58204","DOI":"10.7554\/eLife.58204","volume":"9","author":"PL Theard","year":"2020","unstructured":"Theard PL, Sheffels E, Sealover NE, Linke AJ, Pratico DJ, Kortum RL. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer. Elife. 2020;9:e58204.","journal-title":"Elife"},{"key":"2632_CR41","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.21037\/tlcr-24-570","volume":"13","author":"G Hamilton","year":"2024","unstructured":"Hamilton G, Stickler S, Ermakov M, Eggerstorfer MT, Nocera FP, Hohenegger M, et al. Characterization of the BH1406 non-small cell lung cancer (NSCLC) cell line carrying an activating SOS1 mutation. Transl Lung Cancer Res. 2024;13:2987\u201397.","journal-title":"Transl Lung Cancer Res"},{"key":"2632_CR42","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.3390\/ijms26062579","volume":"26","author":"D Mannino","year":"2025","unstructured":"Mannino D, Basilotta R, De Luca F, Casili G, Esposito E, Paterniti I. KRAS-SOS-1 Inhibition as new pharmacological target to counteract Anaplastic Thyroid Carcinoma (ATC). Int J Mol Sci. 2025;26:2579.","journal-title":"Int J Mol Sci"},{"key":"2632_CR43","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41598-025-87027-2","volume":"15","author":"S Stickler","year":"2025","unstructured":"Stickler S, Lang C, Rieche M, Eggerstorfer MT, Hohenegger M, Hochmair M, et al. Characterization of a pleomorphic rhabdomyosarcoma cell line. Sci Rep. 2025;15:2893.","journal-title":"Sci Rep"},{"key":"2632_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.omto.2021.11.010","volume":"23","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li C, Su R, Yin Z, Huang G, Yang J, et al. Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML. Mol Ther Oncolytics. 2021;23:560\u201370.","journal-title":"Mol Ther Oncolytics"},{"key":"2632_CR45","doi-asserted-by":"publisher","first-page":"e2313137120","DOI":"10.1073\/pnas.2313137120","volume":"120","author":"BR Daley","year":"2023","unstructured":"Daley BR, Vieira HM, Rao C, Hughes JM, Beckley ZM, Huisman DH, et al. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proc Natl Acad Sci U S A. 2023;120:e2313137120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2632_CR46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","volume":"5","author":"V Thatikonda","year":"2024","unstructured":"Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow CA, Albrecht C, et al. Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance. Nat Cancer. 2024;5:1352\u201370.","journal-title":"Nat Cancer"},{"key":"2632_CR47","doi-asserted-by":"publisher","first-page":"e2422943122","DOI":"10.1073\/pnas.2422943122","volume":"122","author":"FC Baltan\u00e1s","year":"2025","unstructured":"Baltan\u00e1s FC, Kramer-Drauberg M, Garc\u00eda-Navas R, Patrucco E, Petrini E, Arnhof H, et al. SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRASG12D inhibitor in KRAS LUAD. Proc Natl Acad Sci U S A. 2025;122:e2422943122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2632_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/0008-5472.CAN-24-1093","volume":"85","author":"Z Luo","year":"2025","unstructured":"Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, et al. Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL-positive leukemia. Cancer Res. 2025;85:101\u201317.","journal-title":"Cancer Res"},{"key":"2632_CR49","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/1535-7163.MCT-23-0870","volume":"23","author":"N Sudhakar","year":"2024","unstructured":"Sudhakar N, Yan L, Qiryaqos F, Engstrom LD, Laguer J, Calinisan A, et al. The SOS1 inhibitor MRTX0902 Blocks KRAS activation and demonstrates antitumor activity in cancers dependent on KRAS nucleotide loading. Mol Cancer Ther. 2024;23:1418\u201330.","journal-title":"Mol Cancer Ther"},{"key":"2632_CR50","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/ijms24020997","volume":"24","author":"L Bruggemann","year":"2023","unstructured":"Bruggemann L, Falls Z, Mangione W, Schwartz SA, Battaglia S, Aalinkeel R, et al. Multiscale analysis and validation of effective drug combinations targeting driver KRAS mutations in non-small cell lung cancer. Int J Mol Sci. 2023;24:997.","journal-title":"Int J Mol Sci"},{"key":"2632_CR51","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1158\/1538-7445.AM2025-4373","volume":"85","author":"N Guthof","year":"2025","unstructured":"Guthof N, Xue H, Jerchel-Furau I, Hethey C, Busse J-E, Denner K, et al. Abstract 4373: Discovery and characterization of BAY 3498264: a small molecule inhibitor targeting the RAS-SOS1 interaction. Cancer Res. 2025;85:4373.","journal-title":"Cancer Res"},{"key":"2632_CR52","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1158\/2767-9764.CRC-24-0582","volume":"5","author":"Z Davoudi","year":"2025","unstructured":"Davoudi Z, Dexheimer TS, Coussens NP, Silvers T, Fox RG, Kemp SB, et al. RAS pathway inhibitors combined with targeted agents are active in patient-derived spheroids with oncogenic KRAS variants from multiple cancer types. Cancer research communications. Cancer Res Commun. 2025;5:1779\u201395.","journal-title":"Cancer Res Commun"},{"key":"2632_CR53","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.3390\/cancers14184467","volume":"14","author":"Y Ma","year":"2022","unstructured":"Ma Y, Schulz B, Trakooljul N, Al Ammar M, Sekora A, Sender S, et al. Inhibition of KRAS, MEK and PI3K demonstrate synergistic anti-tumor effects in pancreatic ductal adenocarcinoma cell lines. Cancers (Basel). 2022;14:4467.","journal-title":"Cancers (Basel)"},{"key":"2632_CR54","doi-asserted-by":"publisher","first-page":"101818","DOI":"10.1016\/j.xcrm.2024.101818","volume":"5","author":"M Marasco","year":"2024","unstructured":"Marasco M, Kumar D, Seale T, Borrego SG, Kaplun E, Aricescu I, et al. Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma. Cell Rep Med. 2024;5:101818.","journal-title":"Cell Rep Med"},{"key":"2632_CR55","doi-asserted-by":"publisher","first-page":"112570","DOI":"10.1016\/j.celrep.2023.112570","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim S, Carvajal R, Kim M, Yang HW. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF\/MEK inhibition in melanoma. Cell Rep. 2023;42:112570.","journal-title":"Cell Rep"},{"key":"2632_CR56","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Navas R, G\u00f3mez C, Zamora-Valdivieso B, Calvo-Jimenez S, Calzada N, Fernandez-Medarde A, et al. Targeting SOS1 synergistically enhances efficacy of BCR\/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia. bioRxiv. 2025.\u00a0https:\/\/doi.org\/10.1101\/2025.09.29.679122.","DOI":"10.1101\/2025.09.29.679122"},{"key":"2632_CR57","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1021\/acs.jmedchem.0c01949","volume":"64","author":"J Ramharter","year":"2021","unstructured":"Ramharter J, Kessler D, Ettmayer P, Hofmann MH, Gerstberger T, Gmachl M, et al. One atom makes all the difference: getting a foot in the door between SOS1 and KRAS. J Med Chem. 2021;64:6569\u201380.","journal-title":"J Med Chem"},{"key":"2632_CR58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/0008-5472.CAN-23-3256","volume":"85","author":"BR Daley","year":"2025","unstructured":"Daley BR, Sealover NE, Finniff BA, Hughes JM, Sheffels E, Gerlach D, et al. SOS1 Inhibition enhances the efficacy of KRASG12C inhibitors and delays resistance in lung adenocarcinoma. Cancer Res. 2025;85:118\u201333.","journal-title":"Cancer Res"},{"key":"2632_CR59","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-21-0856","volume":"27","author":"S Suzuki","year":"2021","unstructured":"Suzuki S, Yonesaka K, Teramura T, Takehara T, Kato R, Sakai H, et al. KRAS Inhibitor resistance in MET -Amplified KRAS G12C non\u2013small cell lung cancer induced by RAS- and Non\u2013RAS-mediated cell signaling mechanisms. Clin Cancer Res. 2021;27:5697\u2013707.","journal-title":"Clin Cancer Res"},{"key":"2632_CR60","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1038\/s41467-023-41583-1","volume":"14","author":"FC Baltan\u00e1s","year":"2023","unstructured":"Baltan\u00e1s FC, Garc\u00eda-Navas R, Rodr\u00edguez-Ramos P, Calzada N, Cuesta C, Borrajo J, et al. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma. Nat Commun. 2023;14:5856.","journal-title":"Nat Commun"},{"key":"2632_CR61","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/1538-7445.AM2020-1091","volume":"80","author":"D Gerlach","year":"2020","unstructured":"Gerlach D, Gmachl M, Ramharter J, Teh J, Fu S-C, Trapani F, et al. Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan. Cancer Res. 2020;80:1091.","journal-title":"Cancer Res"},{"key":"2632_CR62","doi-asserted-by":"publisher","first-page":"eaea2788","DOI":"10.1126\/scisignal.aea2788","volume":"18","author":"BR Daley","year":"2025","unstructured":"Daley BR, Theard PL, Hughes JM, Finniff BA, Hofmann MH, Kostyrko K, et al. SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR -mutant lung cancer. Sci Signal. 2025;18:eaea2788.","journal-title":"Sci Signal"},{"key":"2632_CR63","doi-asserted-by":"publisher","unstructured":"Papadimitropoulou A, Charalampous C, Kogionou P, Reinhardt D, Sonntag J, Gavalas A, et al. Pharmacological targeting of SOS1-RAS interaction triggers pancreatic \u03b2-cell proliferation and sustainably reverses diabetic hyperglycemia. BiorXiv. 2025. https:\/\/doi.org\/10.1101\/2025.06.03.657628.","DOI":"10.1101\/2025.06.03.657628"},{"key":"2632_CR64","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1021\/acs.jmedchem.2c00741","volume":"65","author":"JM Ketcham","year":"2022","unstructured":"Ketcham JM, Haling J, Khare S, Bowcut V, Briere DM, Burns AC, et al. Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein-protein interaction. J Med Chem. 2022;65:9678\u201390.","journal-title":"J Med Chem"},{"key":"2632_CR65","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1158\/1538-7445.AM2024-7268","volume":"84","author":"N Sudhakar","year":"2024","unstructured":"Sudhakar N, Yan L, Qiryaqos F, Laguer J, Briere D, Hebbert A, et al. Abstract 7268: The SOS1 inhibitor MRTX0902 demonstrates activity across cancer models with mutations in proximal components of the RAS-MAPK pathway. Cancer Res. 2024;84:7268.","journal-title":"Cancer Res"},{"key":"2632_CR66","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1158\/1538-7445.AM2021-1273","volume":"81","author":"A Buckl","year":"2021","unstructured":"Buckl A, Quintana E, Lee GJ, Shifrin N, Zhong M, Garrenton LS, et al. Abstract 1273: Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction. Cancer Res. 2021;81:1273.","journal-title":"Cancer Res"},{"key":"2632_CR67","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1021\/acsmedchemlett.2c00490","volume":"14","author":"M Liu","year":"2023","unstructured":"Liu M, Zhou G, Su W, Gu Y, Gao M, Wang K, et al. Design, synthesis, and bioevaluation of pyrido[2,3-d]pyrimidin-7-ones as potent SOS1 inhibitors. ACS Med Chem Lett. 2023;14:183\u201390.","journal-title":"ACS Med Chem Lett"},{"key":"2632_CR68","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1158\/1535-7163.MCT-24-0049","volume":"23","author":"F Xiao","year":"2024","unstructured":"Xiao F, Wang K, Wang X, Li H, Hu Z, Ren X, et al. Discovery of RGT-018: a potent, selective, and orally bioavailable SOS1 inhibitor for KRAS-driven cancers. Mol Cancer Ther. 2024;23:1703\u201316.","journal-title":"Mol Cancer Ther"},{"key":"2632_CR69","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1158\/1538-7445.AM2024-3313","volume":"84","author":"DH Ki","year":"2024","unstructured":"Ki DH, Yu H, Kim D, Jeon Y, Jo S, Nam J, et al. Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction. Cancer Res. 2024;84:3313.","journal-title":"Cancer Res"},{"key":"2632_CR70","doi-asserted-by":"publisher","first-page":"107833","DOI":"10.1016\/j.bioorg.2024.107833","volume":"153","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Huang C, Hou Q, Jiang W, Cheng J, Wu X. Design, synthesis, and evaluation of dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) inhibitors for the treatment of cancers. Bioorg Chem. 2024;153:107833.","journal-title":"Bioorg Chem"},{"key":"2632_CR71","doi-asserted-by":"publisher","first-page":"130344","DOI":"10.1016\/j.bmcl.2025.130344","volume":"128","author":"X Chen","year":"2025","unstructured":"Chen X, Ma X, Yang Z, Mao M, Niu W, Zhang C, et al. Development and biological evaluation of novel SOS1 inhibitors featuring 5,8-dihydropyrido[4,3-d]pyrimidin-7(6H)-one scaffold. Bioorg Med Chem Lett. 2025;128:130344.","journal-title":"Bioorg Med Chem Lett"},{"key":"2632_CR72","doi-asserted-by":"publisher","first-page":"117065","DOI":"10.1016\/j.ejmech.2024.117065","volume":"282","author":"L Qing","year":"2025","unstructured":"Qing L, Cheng Z, Xu J, Wang Z, Li Y, Gauthier M, et al. Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: a joint view of experiments and simulations. Eur J Med Chem. 2025;282:117065.","journal-title":"Eur J Med Chem"},{"key":"2632_CR73","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1021\/acsmedchemlett.5c00300","volume":"16","author":"D Li","year":"2025","unstructured":"Li D, Xie Q, Yang M, Sun K, Jiang S, Yu S, et al. Identification of novel 2-(Azetidin-3-ylamino)nicotinamide derivatives as potent KRAS::SOS1 inhibitors. ACS Med Chem Lett. 2025;16:1626\u201333.","journal-title":"ACS Med Chem Lett"},{"key":"2632_CR74","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1021\/acsmedchemlett.5c00152","volume":"16","author":"X Pang","year":"2025","unstructured":"Pang X, Cui D, Zhang Q, Liang H, Liu R, Lv B, et al. Design and Development of Potent SOS1 Inhibitors with Effective Antitumor Activities In Vitro \/ In Vivo. ACS Med Chem Lett. 2025;16:1538\u201345.","journal-title":"ACS Med Chem Lett"},{"key":"2632_CR75","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1021\/acsmedchemlett.4c00156","volume":"15","author":"D Li","year":"2024","unstructured":"Li D, Xie Q, Yang M, Cai Y, Sun K, Jiang S, et al. Lead identification of novel naphthyridine derivatives as potent SOS1 inhibitors. ACS Med Chem Lett. 2024;15:958\u201364.","journal-title":"ACS Med Chem Lett"},{"key":"2632_CR76","doi-asserted-by":"publisher","first-page":"LB031","DOI":"10.1158\/1538-7445.AM2024-LB031","volume":"84","author":"Q Xie","year":"2024","unstructured":"Xie Q, Li D, Jiang S, Zhu J, Yu S, Yang M, et al. Abstract LB031: Discovery and characterization of HH100937, a potent and selective SOS1 inhibitor demonstrates synergistic efficacy in combination with KRAS\/MAPK therapies. Cancer Res. 2024;84:LB031.","journal-title":"Cancer Res"},{"key":"2632_CR77","doi-asserted-by":"publisher","first-page":"LB429","DOI":"10.1158\/1538-7445.AM2025-LB429","volume":"85","author":"J Choi","year":"2025","unstructured":"Choi J, Park W, Jeon S, Moon H, Kang Y, Lee EY, et al. Abstract LB429: Discovery of a novel SOS1-KRASmulti inhibitor, HM101207, demonstrates a broad-spectrum antitumor activity across KRAS-MAPK mutant cancers. Cancer Res. 2025;85:LB429.","journal-title":"Cancer Res"},{"key":"2632_CR78","doi-asserted-by":"publisher","first-page":"A066","DOI":"10.1158\/1535-7163.TARG-25-A066","volume":"24","author":"SH Jung","year":"2025","unstructured":"Jung SH, Choi J, Park W, Jeon S, Moon H, Byun J, et al. Abstract A066: SOS1-panKRAS modulator, HM101207: a top candidate to control KRAS-MAPK-driven cancers through strong synergy with vertical inhibitors. Mol Cancer Ther. 2025;24:A066.","journal-title":"Mol Cancer Ther"},{"key":"2632_CR79","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1158\/1538-7445.AM2025-4374","volume":"85","author":"Y Li","year":"2025","unstructured":"Li Y, Zang Y, Hu W, Zhou Y, Liu L, Zhang X, et al. Abstract 4374: Discovery of a highly potent and efficacious SOS1 inhibitor targeting KRAS-driven cancers. Cancer Res. 2025;85:4374.","journal-title":"Cancer Res"},{"key":"2632_CR80","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1158\/1538-7445.AM2025-4376","volume":"85","author":"H Wang","year":"2025","unstructured":"Wang H, Gray F, Atsriku C, Levinson AM, Placzek A, Houang EM, et al. Abstract 4376: Preclinical characterization of SGR-4174, a potent and selective SOS1 inhibitor for the treatment of pan KRAS mutant cancers in combination with KRAS pathway inhibitors. Cancer Res. 2025;85:4376.","journal-title":"Cancer Res"},{"key":"2632_CR81","doi-asserted-by":"publisher","first-page":"e202400008","DOI":"10.1002\/cbic.202400008","volume":"25","author":"S Ikram","year":"2024","unstructured":"Ikram S, Sayyah E, Durda\u011f\u0131 S. Identifying potential SOS1 inhibitors via virtual screening of multiple small molecule libraries against KRAS-SOS1 interaction. ChemBioChem. 2024;25:e202400008.","journal-title":"ChemBioChem"},{"key":"2632_CR82","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1039\/D4MD00063C","volume":"15","author":"L Duo","year":"2024","unstructured":"Duo L, Chen Y, Liu Q, Ma Z, Farjudian A, Ho WY, et al. Discovery of novel SOS1 inhibitors using machine learning. RSC Med Chem. 2024;15:1392\u2013403.","journal-title":"RSC Med Chem"},{"key":"2632_CR83","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1021\/acsmedchemlett.4c00602","volume":"16","author":"AE Leffler","year":"2025","unstructured":"Leffler AE, Houang EM, Gray F, Placzek AT, Ruvinsky AM, Bell JA, et al. Exploiting solvent exposed salt-bridge interactions for the discovery of potent inhibitors of SOS1 using free-energy perturbation simulations. ACS Med Chem Lett. 2025;16:444\u201353.","journal-title":"ACS Med Chem Lett"},{"key":"2632_CR84","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.3390\/ijms26073293","volume":"26","author":"Z Sarica","year":"2025","unstructured":"Sarica Z, Kurkcuoglu O, Sungur FA. In Silico Identification of Putative Allosteric Pockets and inhibitors for the KRASG13D-SOS1 complex in cancer therapy. Int J Mol Sci. 2025;26:3293.","journal-title":"Int J Mol Sci"},{"key":"2632_CR85","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1021\/acsmedchemlett.5c00302","volume":"16","author":"S Bonomo","year":"2025","unstructured":"Bonomo S, Gibault F, Bagal SK, Blackwell JH, Breed J, Collie GW, et al. Focused structure-based virtual screening identifies novel inhibitors of SOS1. ACS Med Chem Lett. 2025;16:1905\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"2632_CR86","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"2632_CR87","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res. 2015;13:1325\u201335.","journal-title":"Mol Cancer Res"},{"key":"2632_CR88","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1021\/acs.biochem.9b00532","volume":"58","author":"Z Moghadamchargari","year":"2019","unstructured":"Moghadamchargari Z, Huddleston J, Shirzadeh M, Zheng X, Clemmer DE, Raushel M. Intrinsic GTPase Activity of K-RAS monitored by native mass spectrometry. Biochemistry. 2019;58:3396\u2013405.","journal-title":"Biochemistry"},{"key":"2632_CR89","doi-asserted-by":"publisher","first-page":"105650","DOI":"10.1016\/j.jbc.2024.105650","volume":"300","author":"AK Sharma","year":"2024","unstructured":"Sharma AK, Pei J, Yang Y, Dyba M, Smith B, Rabara D, et al. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR. J Biol Chem. 2024;300:105650.","journal-title":"J Biol Chem"},{"key":"2632_CR90","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1158\/0008-5472.CAN-24-2983","volume":"85","author":"J-L Shan","year":"2025","unstructured":"Shan J-L, Zhang K-M, Zhong W-Q, Yang X-Y, Li Z-L, Huang Y, et al. Reactivating cGAS-STING Signaling by targeting SOS1 enhances antitumor immunity in NRAS-mutant tumors. Cancer Res. 2025;85:3015\u201331.","journal-title":"Cancer Res"},{"key":"2632_CR91","doi-asserted-by":"publisher","first-page":"16432","DOI":"10.1021\/acs.jmedchem.2c01300","volume":"65","author":"Y Bian","year":"2022","unstructured":"Bian Y, Alem D, Beato F, Hogenson TL, Yang X, Jiang K, et al. Development of SOS1 inhibitor-based degraders to target KRAS-mutant colorectal cancer. J Med Chem. 2022;65:16432\u201350.","journal-title":"J Med Chem"},{"key":"2632_CR92","doi-asserted-by":"publisher","first-page":"8875","DOI":"10.1021\/acs.jmedchem.8b01108","volume":"61","author":"TR Hodges","year":"2018","unstructured":"Hodges TR, Abbott JR, Little AJ, Sarkar D, Salovich JM, Howes JE, et al. Discovery and structure-based optimization of benzimidazole-derived activators of SOS1-mediated nucleotide exchange on RAS. J Med Chem. 2018;61:8875\u201394.","journal-title":"J Med Chem"},{"key":"2632_CR93","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1021\/acs.jmedchem.3c00075","volume":"66","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Zhou G, Zhou C, Fan Z, Cui R, Li Y, et al. Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers. J Med Chem. 2023;66:4197\u2013214.","journal-title":"J Med Chem"},{"key":"2632_CR94","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1021\/acs.jmedchem.3c01598","volume":"67","author":"Y Lv","year":"2024","unstructured":"Lv Y, Yang Z, Chen Y, Ma X, Guo M, Zhang C, et al. A Potent SOS1 PROTAC degrader with synergistic efficacy in combination with KRAS G12C inhibitor. J Med Chem. 2024;67:2487\u2013511.","journal-title":"J Med Chem"},{"key":"2632_CR95","doi-asserted-by":"publisher","first-page":"117661","DOI":"10.1016\/j.bmc.2024.117661","volume":"103","author":"H Li","year":"2024","unstructured":"Li H, Chai M, Chen Y, Zhou F, Ren X, Xu J, et al. Discovery of LHF418 as a new potent SOS1 PROTAC degrader. Bioorg Med Chem. 2024;103:117661.","journal-title":"Bioorg Med Chem"},{"key":"2632_CR96","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1158\/1535-7163.MCT-23-0513","volume":"23","author":"K Begovich","year":"2024","unstructured":"Begovich K, Schoolmeesters A, Rajapakse N, Martinez-Terroba E, Kumar M, Shakya A, et al. Cereblon-based bifunctional degrader of SOS1, BTX-6654, targets multiple KRAS mutations and inhibits tumor growth. Mol Cancer Ther. 2024;23:407\u201320.","journal-title":"Mol Cancer Ther"},{"key":"2632_CR97","doi-asserted-by":"publisher","first-page":"e15192","DOI":"10.1200\/JCO.2024.42.16_suppl.e15192","volume":"42","author":"K Begovich","year":"2024","unstructured":"Begovich K, Schoolmeesters A, Martinez-Terroba E, Rajapakse N, Liu Q, Shakya A, et al. Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRAS- and RTK-driven cancers. J Clin Oncol. 2024;42:e15192.","journal-title":"J Clin Oncol"},{"key":"2632_CR98","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1021\/acs.jmedchem.3c02135","volume":"67","author":"X Pang","year":"2024","unstructured":"Pang X, Cui D, Lv B, Wang CY. Discovery of Potent SOS1 PROTACs with effective antitumor activities against NCI-H358 tumor cells in vitro\/in vivo. J Med Chem. 2024;67:1563\u201379.","journal-title":"J Med Chem"},{"key":"2632_CR99","doi-asserted-by":"publisher","first-page":"129780","DOI":"10.1016\/j.bmcl.2024.129780","volume":"107","author":"K Wang","year":"2024","unstructured":"Wang K, Zhou Z, Ma X, Xu J, Xu W, Zhou G, et al. Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor. Bioorg Med Chem Lett. 2024;107:129780.","journal-title":"Bioorg Med Chem Lett"},{"key":"2632_CR100","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1158\/1538-7445.AM2025-7008","volume":"85","author":"J Kim","year":"2025","unstructured":"Kim J, Park JY, Woo Y, Lee S, Suh B, Kim HW, et al. Abstract 7008: Development of a potent SOS1 degrader exhibiting superior combination effects with anti-cancer drugs in various tumor models. Cancer Res. 2025;85:7008.","journal-title":"Cancer Res"},{"key":"2632_CR101","doi-asserted-by":"publisher","first-page":"6613","DOI":"10.3390\/ijms22126613","volume":"22","author":"FC Baltan\u00e1s","year":"2021","unstructured":"Baltan\u00e1s FC, Garc\u00eda-Navas R, Santos E. Sos2 comes to the fore: Differential functionalities in physiology and pathology. Int J Mol Sci. 2021;22:6613.","journal-title":"Int J Mol Sci"},{"key":"2632_CR102","doi-asserted-by":"publisher","first-page":"S591","DOI":"10.1016\/j.annonc.2021.08.1046","volume":"32","author":"ML Johnson","year":"2021","unstructured":"Johnson ML, Gort E, Pant S, Lolkema MP, Sebastian M, Scheffler M, et al. 524P A phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: a snapshot analysis. Ann Oncol. 2021;32:S591\u20132.","journal-title":"Ann Oncol"},{"key":"2632_CR103","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1038\/s41388-021-01886-3","volume":"40","author":"R Garcia-Navas","year":"2021","unstructured":"Garcia-Navas R, Liceras-Boillos P, Gomez C, Baltan\u00e1s FC, Nuevo-Tapioles C, Cuezva J, et al. Critical requirement of SOS1 RAS-GEF function for mitochondrial dynamics, metabolism and redox homeostasis. Oncogene. 2021;40:4538\u201351.","journal-title":"Oncogene"},{"key":"2632_CR104","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.1128\/MCB.00049-18","volume":"38","author":"P Liceras-Boillos","year":"2018","unstructured":"Liceras-Boillos P, Jimeno D, Garc\u00eda-Navas R, Lorenzo-Mart\u00edn LF, Menacho-Marquez M, Segrelles C, et al. Differential role of the RasGEFs Sos1 and Sos2 in mouse skin homeostasis and carcinogenesis. Mol Cell Biol. 2018;38:e00049\u201318.","journal-title":"Mol Cell Biol"},{"key":"2632_CR105","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/acs.jmedchem.3c02140","volume":"67","author":"CR Smith","year":"2024","unstructured":"Smith CR, Chen D, Christensen JG, Coulombe R, F\u00e9thi\u00e8re J, Gunn RJ, et al. Discovery of five SOS2 fragment hits with binding modes determined by SOS2 X-ray cocrystallography. J Med Chem. 2024;67:774\u201381.","journal-title":"J Med Chem"},{"key":"2632_CR106","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1021\/acs.jmedchem.4c02007","volume":"68","author":"KM Zak","year":"2025","unstructured":"Zak KM, Waterson AG, Geist L, Braun N, Hauer K, Rumpel K, et al. Discovery of small molecules that bind to son of sevenless 2 (SOS2). J Med Chem. 2025;68:2680\u201393.","journal-title":"J Med Chem"},{"key":"2632_CR107","doi-asserted-by":"publisher","first-page":"S1894","DOI":"10.4103\/jpbs.jpbs_534_25","volume":"17","author":"AA Alzain","year":"2025","unstructured":"Alzain AA, Almogaddam MA, Makki AA, Edris A, Mohamed HM, Ehaimir SY, et al. Screening enamine fragments library in the quest for novel SOS2 inhibitors: pharmacophore modelling, molecular docking, MMGBSA calculations, and MD simulation. J Pharm Bioallied Sci. 2025;17:S1894\u20139.","journal-title":"J Pharm Bioallied Sci"},{"key":"2632_CR108","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-024-08283-2","volume":"637","author":"A Cuevas-Navarro","year":"2025","unstructured":"Cuevas-Navarro A, Pourfarjam Y, Hu F, Rodriguez DJ, Vides A, Sang B, et al. Pharmacological restoration of GTP hydrolysis by mutant RAS. Nature. 2025;637:224\u20139.","journal-title":"Nature"},{"key":"2632_CR109","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/emboj.2010.7","volume":"29","author":"M Drosten","year":"2010","unstructured":"Drosten M, Dhawahir A, Sum EYM, Urosevic J, Lechuga CG, Esteban LM, et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 2010;29:1091\u2013104.","journal-title":"EMBO J"},{"key":"2632_CR110","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1158\/2159-8290.CD-22-1467","volume":"13","author":"WH Hsu","year":"2023","unstructured":"Hsu WH, Labella KA, Lin Y, Xu P, Lee R, Hsieh CE, et al. Oncogenic KRAS drives lipofibrogenesis to promote angiogenesis and colon cancer progression. Cancer Discov. 2023;13:2652\u201373.","journal-title":"Cancer Discov"},{"key":"2632_CR111","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1101\/gad.351037.123","volume":"37","author":"J Han","year":"2023","unstructured":"Han J, Xu J, Liu Y, Liang S, LaBella KA, Chakravarti D, et al. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer. Genes Dev. 2023;37:818\u201328.","journal-title":"Genes Dev"},{"key":"2632_CR112","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1158\/2159-8290.CD-24-0100","volume":"4","author":"KL Donahue","year":"2024","unstructured":"Donahue KL, Watkoske HR, Kadiyala P, Du W, Brown K, Scales MK, et al. Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth. Cancer Discov. 2024;4:1964\u201389.","journal-title":"Cancer Discov"},{"key":"2632_CR113","doi-asserted-by":"publisher","first-page":"e156891","DOI":"10.1172\/JCI156891","volume":"132","author":"T Manabe","year":"2022","unstructured":"Manabe T, Bivona TG. Remodeling of the tumor\/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. J Clin Invest. 2022;132:e156891.","journal-title":"J Clin Invest"},{"key":"2632_CR114","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s11864-022-01033-4","volume":"23","author":"M Bungaro","year":"2022","unstructured":"Bungaro M, Novello S, Passiglia F. Targeting KRASp.G12C Mutation in advanced non-small cell lung cancer: a new era has begun. Curr Treat Options Oncol. 2022;23:1699\u2013720.","journal-title":"Curr Treat Options Oncol"},{"key":"2632_CR115","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/0008-5472.CAN-23-2504","volume":"84","author":"V Kumarasamy","year":"2024","unstructured":"Kumarasamy V, Wang J, Frangou C, Wan Y, Dynka A, Rosenheck H, et al. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 2024;84:1115\u201332.","journal-title":"Cancer Res"},{"key":"2632_CR116","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13046-025-03369-9","volume":"44","author":"J Wu","year":"2025","unstructured":"Wu J, Xie K, Zhang Y, Zhang W, Cheng R, Zhang Y, et al. RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer. J Experimental Clin Cancer Res. 2025;44:106.","journal-title":"J Experimental Clin Cancer Res"},{"key":"2632_CR117","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.4049\/jimmunol.1500579","volume":"195","author":"A Baruzzi","year":"2015","unstructured":"Baruzzi A, Remelli S, Lorenzetto E, Sega M, Chignola R, Berton G. Sos1 regulates macrophage podosome assembly and macrophage invasive capacity. J Immunol. 2015;195:4900\u201312.","journal-title":"J Immunol"},{"key":"2632_CR118","first-page":"14","volume":"1","author":"P Liceras-Boillos","year":"2016","unstructured":"Liceras-Boillos P, Garc\u00eda-Navas R, Ginel-Picardo A, Anta B, P\u00e9rez-Andr\u00e9s M, Lillo C, et al. Sos1 disruption impairs cellular proliferation and viability through an increase in mitochondrial oxidative stress in primary MEFs. Oncogene. 2016;1:14.","journal-title":"Oncogene"},{"key":"2632_CR119","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/JLB.2HI0918-359RR","volume":"106","author":"S Suire","year":"2019","unstructured":"Suire S, Baltanas FC, Segonds-Pichon A, Davidson K, Santos E, Hawkins PT, et al. Frontline Science: TNF-\u03b1 and GM-CSF1 priming augments the role of SOS1\/2 in driving activation of Ras, PI3K-\u03b3, and neutrophil proinflammatory responses. J Leukoc Biol. 2019;106:815\u201322.","journal-title":"J Leukoc Biol"},{"key":"2632_CR120","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12967-023-04486-9","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xie B, Chen Q. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment. J Transl Med. 2023;21:595.","journal-title":"J Transl Med"},{"key":"2632_CR121","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1083\/jcb.200108035","volume":"156","author":"M Innocenti","year":"2002","unstructured":"Innocenti M, Tenca P, Frittoli E, Faretta M, Tocchetti A, Di Fiore PP, et al. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol. 2002;156:125\u201336.","journal-title":"J Cell Biol"},{"key":"2632_CR122","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1083\/jcb.200103146","volume":"154","author":"G Scita","year":"2001","unstructured":"Scita G, Tenca P, Areces LB, Tocchetti A, Frittoli E, Giardina G, et al. An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin\u2013polymerizing machine. J Cell Biol. 2001;154:1031\u201344.","journal-title":"J Cell Biol"},{"key":"2632_CR123","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/leu.2017.267","volume":"32","author":"S Gerboth","year":"2018","unstructured":"Gerboth S, Frittoli E, Palamidessi A, Baltanas FC, Salek M, Rappsilber J, et al. Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis. Leukemia. 2018;32:820\u20137.","journal-title":"Leukemia"},{"key":"2632_CR124","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.3390\/cancers14163893","volume":"14","author":"C G\u00f3mez","year":"2022","unstructured":"G\u00f3mez C, Garcia-Navas R, Baltan\u00e1s FC, Fuentes-Mateos R, Fern\u00e1ndez-Medarde A, Calzada N, et al. Critical requirement of SOS1 for development of BCR\/ABL-driven chronic myelogenous leukemia. Cancers (Basel). 2022;14:3893.","journal-title":"Cancers (Basel)"},{"key":"2632_CR125","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/ajmg.a.61485","volume":"182","author":"AM Gross","year":"2020","unstructured":"Gross AM, Frone M, Gripp KW, Gelb BD, Schoyer L, Schill L, et al. Advancing RAS\/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies. Am J Med Genet A. 2020;182:866\u201376.","journal-title":"Am J Med Genet A"},{"key":"2632_CR126","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/mc.23543","volume":"2","author":"D Alem","year":"2023","unstructured":"Alem D, Yang X, Beato F, Sarcar B, Tassielli AF, Dai R, et al. Translational relevance of SOS1 targeting for KRAS -mutant colorectal cancer. Mol Carcinog. 2023;2:1025\u201337.","journal-title":"Mol Carcinog"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02632-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02632-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:02:41Z","timestamp":1780632161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02632-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2632"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02632-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}